All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

MolMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AGC to Complete the Acquisition of MolMed on July 31, 2020

Lead Product(s): Zalmoxis

Therapeutic Area: Oncology Product Name: Zalmoxis

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: AGC Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 27, 2020

Details:

Through the acquisition of Molmed, AGC will enter into the innovative gene & cell therapy field to expand its CDMO offering to the area where there is a strong imbalance between demand and supply of specific skills and production capacity worldwide.